Breakfast or not? study tests Food's impact on new pill

NCT ID NCT07508462

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 trial tested how a high-fat or low-fat meal changes the way the body absorbs ammoxetine, a potential antidepressant. Eighteen healthy adults each took a single 60 mg dose under three different meal conditions. The goal was to see if food affects drug levels in the blood, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ammoxetine hydrochloride
What this could lead to
If successful, this study could help determine whether ammoxetine should be taken with or without food for best absorption.
What could go wrong
This is a small, early-stage trial in healthy people, not patients. Results may not predict real-world effects or safety in those with depression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Fourth Hospital of Hebei Medical University, Hebei Tumor Hospital

    Shijiazhuang, Hebei, 050035, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.